Close Menu

antibodies

The company's commercial testing continues to focus on patients with identified lung nodules, but the new data is the strongest yet to support a shift to upfront cancer detection.

The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.

The deals cover Native Antigen's native and recombinant viral and bacterial antigens, antibodies, and immunoassays in certain European and Asian markets.

The partnership follows a strategic collaboration between Twist and LakePharma, announced last week, that involves the same technology.

The firms will use AbCellera's antibody discovery platform, which combines a variety of technologies including next-generation sequencing and bioinformatics.

As part of the Human Vaccines Project, researchers sequenced samples from three adults and three infants to identify sets of shared and unique circulating B cell receptors.

The companies will use Berkeley Lights' technology to improve Pfizer's monoclonal antibody discovery and gene editing workflows.

The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.

The custom-made software will also allow Twist's biopharmaceutical customers to access a proprietary G-protein coupled receptor target library.

Researchers discuss the need for antibody standards at a meeting, NPR reports.

Pages

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.